Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences
Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in major investor and scientific conferences in May 2025. The company's leadership team, including Executive Chairman Dr. Pravin Dugel, will present at the Citizens JMP Life Sciences Conference (May 7) and Bank of America Global Healthcare Conference (May 13).
The company will have significant presence at key scientific events including Eyecelerator, ARVO 2025, and Retina World Congress. Notable presentations will focus on their axitinib hydrogel (OTX-TKI) research for diabetic retinopathy and macular degeneration. Multiple studies will be presented, including results from the HELIOS trial and research on retinal leakage assessment.
Key executives participating include Chief Medical Officer Dr. Waheed, Chief Business Officer Saroj, and Chief Strategy Officer Dr. Nayak. The presentations will showcase Ocular's advances in novel drug delivery approaches for retinal conditions.
Ocular Therapeutix (NASDAQ: OCUL) ha annunciato la sua partecipazione a importanti conferenze per investitori e scientifiche nel maggio 2025. Il team dirigenziale dell'azienda, incluso il Presidente Esecutivo Dr. Pravin Dugel, presenterà alla Citizens JMP Life Sciences Conference (7 maggio) e alla Bank of America Global Healthcare Conference (13 maggio).
L'azienda avrà una presenza significativa in eventi scientifici chiave come Eyecelerator, ARVO 2025 e Retina World Congress. Le presentazioni principali si concentreranno sulla ricerca relativa all'idrogel di axitinib (OTX-TKI) per la retinopatia diabetica e la degenerazione maculare. Verranno presentati vari studi, inclusi i risultati del trial HELIOS e ricerche sulla valutazione delle perdite retiniche.
I dirigenti principali coinvolti includono il Chief Medical Officer Dr. Waheed, il Chief Business Officer Saroj e il Chief Strategy Officer Dr. Nayak. Le presentazioni metteranno in luce i progressi di Ocular nelle nuove metodologie di somministrazione di farmaci per le patologie retiniche.
Ocular Therapeutix (NASDAQ: OCUL) ha anunciado su participación en importantes conferencias para inversores y científicas en mayo de 2025. El equipo directivo de la compañía, incluido el Presidente Ejecutivo Dr. Pravin Dugel, presentará en la Citizens JMP Life Sciences Conference (7 de mayo) y en la Bank of America Global Healthcare Conference (13 de mayo).
La empresa tendrá una presencia destacada en eventos científicos clave como Eyecelerator, ARVO 2025 y Retina World Congress. Las presentaciones principales se centrarán en su investigación con hidrogel de axitinib (OTX-TKI) para la retinopatía diabética y la degeneración macular. Se presentarán varios estudios, incluidos los resultados del ensayo HELIOS y la investigación sobre la evaluación de fugas retinianas.
Los ejecutivos principales que participarán incluyen al Director Médico Dr. Waheed, al Director Comercial Saroj y al Director de Estrategia Dr. Nayak. Las presentaciones mostrarán los avances de Ocular en nuevos métodos de administración de fármacos para enfermedades retinianas.
Ocular Therapeutix (NASDAQ: OCUL)은 2025년 5월 주요 투자자 및 과학 컨퍼런스에 참여할 것이라고 발표했습니다. 경영진 팀에는 집행 의장 Dr. Pravin Dugel이 포함되며, Citizens JMP Life Sciences Conference(5월 7일)와 Bank of America Global Healthcare Conference(5월 13일)에서 발표할 예정입니다.
회사는 Eyecelerator, ARVO 2025, Retina World Congress 등 주요 과학 행사에 크게 참여합니다. 주목할 만한 발표는 당뇨병성 망막병증과 황반변성을 위한 악시티닙 하이드로겔(OTX-TKI) 연구에 초점을 맞춥니다. HELIOS 임상시험 결과와 망막 누출 평가 연구를 포함한 여러 연구가 발표될 예정입니다.
참여하는 주요 임원으로는 최고 의료 책임자 Dr. Waheed, 최고 사업 책임자 Saroj, 최고 전략 책임자 Dr. Nayak가 있습니다. 발표를 통해 망막 질환을 위한 혁신적인 약물 전달 방법에서 Ocular의 진보를 선보일 것입니다.
Ocular Therapeutix (NASDAQ : OCUL) a annoncé sa participation à d'importantes conférences pour investisseurs et scientifiques en mai 2025. L'équipe dirigeante de la société, incluant le président exécutif Dr Pravin Dugel, présentera lors de la Citizens JMP Life Sciences Conference (7 mai) et de la Bank of America Global Healthcare Conference (13 mai).
L'entreprise sera fortement présente lors d'événements scientifiques majeurs tels que Eyecelerator, ARVO 2025 et le Retina World Congress. Les présentations principales porteront sur leurs recherches concernant l'hydrogel d'axitinib (OTX-TKI) pour la rétinopathie diabétique et la dégénérescence maculaire. Plusieurs études seront présentées, incluant les résultats de l'essai HELIOS et des recherches sur l'évaluation des fuites rétiniennes.
Les cadres clés participant comprennent le directeur médical Dr Waheed, le directeur commercial Saroj et le directeur de la stratégie Dr Nayak. Les présentations mettront en lumière les avancées d'Ocular dans les nouvelles approches de délivrance de médicaments pour les affections rétiniennes.
Ocular Therapeutix (NASDAQ: OCUL) hat seine Teilnahme an bedeutenden Investoren- und Wissenschaftskonferenzen im Mai 2025 angekündigt. Das Führungsteam des Unternehmens, einschließlich Executive Chairman Dr. Pravin Dugel, wird auf der Citizens JMP Life Sciences Conference (7. Mai) und der Bank of America Global Healthcare Conference (13. Mai) präsentieren.
Das Unternehmen wird auf wichtigen wissenschaftlichen Veranstaltungen wie Eyecelerator, ARVO 2025 und dem Retina World Congress stark vertreten sein. Hervorzuhebende Präsentationen konzentrieren sich auf ihre Forschung zum Axitinib-Hydrogel (OTX-TKI) bei diabetischer Retinopathie und Makuladegeneration. Es werden mehrere Studien vorgestellt, darunter Ergebnisse der HELIOS-Studie und Untersuchungen zur Beurteilung von Netzhautlecks.
Wichtige teilnehmende Führungskräfte sind Chief Medical Officer Dr. Waheed, Chief Business Officer Saroj und Chief Strategy Officer Dr. Nayak. Die Präsentationen werden die Fortschritte von Ocular bei neuartigen Wirkstoffabgabemethoden für Netzhauterkrankungen hervorheben.
- Strong scientific presence with multiple presentations at major ophthalmology conferences (ARVO, RWC)
- Active development of OTX-TKI for diabetic retinopathy with multiple clinical trial data presentations
- High-level executive participation in major healthcare investor conferences (Bank of America, Citizens JMP)
- Multiple clinical trials showing progress in axitinib hydrogel development
- None.
BEDFORD, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in the first half of May 2025.
Upcoming Investor Conferences
Citizens JMP Life Sciences Conference 2025:
Fireside Chat Date: Wednesday, May 7, 2025
Fireside Chat Time: 9:00 AM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: New York, NY
Bank of America 2025 Global Healthcare Conference:
Fireside Chat Date: Tuesday, May 13, 2025
Fireside Chat Time: 9:20 AM PT
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Las Vegas, NV
A live webcast of the fireside chats can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.
Upcoming Scientific Conferences
Eyecelerator @ Park City 2025:
Park City, Utah
- Panel Title: Retina in Office
Session 5: I Shall be Released: Novel Drug Delivery Approaches for Glaucoma and Retina
Session Date/Time: Friday, May 2, 2025, 12:30 – 1:30 PM MT
Panelist: Nadia K. Waheed, MD, MPH, Chief Medical Officer
- Panel Title: Retina in OR
Session 5: I Shall be Released: Novel Drug Delivery Approaches for Glaucoma and Retina
Session Date/Time: Friday, May 2, 2025, 12:30 – 1:30 PM MT
Moderator: Namrata Saroj, OD, Chief Business Officer
- Company Presentation: Ocular Therapeutix
Session: Retina - TKI and Drug Delivery Showcase
Presentation Date/Time: Friday, May 2, 2025, 1:38 – 1:45PM MT
Presenter: Sanjay Nayak, MBBS, PhD, Chief Strategy Officer
The Association for Research in Vision and Ophthalmology (ARVO) 2025:
Salt Lake City, Utah
- Presentation Title: Longitudinal quantitative ultra-widefield retinal leakage assessment following a single axitinib hydrogel injection (OTX-TKI) from the HELIOS trial for diabetic retinopathy
Session Date/Time: Tuesday, May 6, 2025, 1:45 – 2:00 PM MT
Location: Ballroom F (Presentation #3311)
Presenter: Neal Shah, MD
- Poster Title: Target and selectivity profiling of axitinib in cell-based and biochemical assays
Session Date/Time: Thursday, May 8, 2025, 11:45 AM – 1:30 PM MT
Location: Hall A-E (Poster #A0179)
Presenter: Chintan Patel, PhD, Director, Nonclinical Development
- Poster Title: Macular volumetric fluid outcomes following intravitreal axitinib hydrogel injection (OTX-TKI) in non-proliferative diabetic retinopathy
Session Date/Time: Thursday, May 8, 2025, 2:00 – 3:45 PM MT
Location: Hall A-E (Poster #A0138)
Presenter: Amy Tang
- Poster Title: Effect of intravitreal axitinib hydrogel injection (OTX-TKI) on ellipsoid zone integrity in non-proliferative diabetic retinopathy
Session Date/Time: Thursday, May 8, 2025, 2:00 – 3:45 PM MT
Location: Hall A-E (Poster #A0140)
Presenter: Paulo Henrique Simoes da Silva, MD
Retina Unplugged at Retina World Congress (RWC) 2025:
Ft. Lauderdale, FL
- Company Presentation: Ocular Therapeutix
Session: Wet AMD, DR, RVO – Part 1
Presentation Date/Time: Thursday, May 8, 2025, 8:27 – 8:32 AM ET
Presenter: Sanjay Nayak, MBBS, PhD, Chief Strategy Officer
- Panel Title: Wet AMD, DR, RVO – Part 1
Panel Date/Time: Thursday, May 8, 2025, 8:33 – 9:06 AM ET
Panelist: Peter K. Kaiser, MD, Chief Development Officer
Retina World Congress (RWC) 2025:
Ft. Lauderdale, FL
- Presentation Title: Axitinib Intravitreal Hydrogel: Update on Clinical Trials
Session: Wet Age-Related Macular Degeneration
Presentation Date/Time: Friday, May 9, 2025, 4:33 – 4:38 PM ET
Presenter: Carl C. Awh, MD, FASRS
- Presentation Title: Update on OTX-TKI DR
Session: Medical Retina: DME and Diabetic Retinopathy
Presentation Date/Time: Saturday, May 10, 2025, 8:44 – 8:49 AM ET
Presenter: Dilsher S. Dhoot, MD, FASRS
- Presentation Title: Volumetric Macular Fluid Analysis of the Impact of a Single Axitinib Intravitreal Injection (OTX-TKI) from the HELIOS Clinical Trial for Diabetic Retinopathy
Session: Medical Retina: DME and Diabetic Retinopathy
Presentation Date/Time: Saturday May 10, 2025, 8:52 – 8:57 AM ET
Presenter: Carl J. Danzig, MD
Exact medical conference presentation times may be subject to change.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged 2 years or older, and in its investigational product candidate PAXTRAVA™ (travoprost intracameral hydrogel or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
Which investor conferences will Ocular Therapeutix (OCUL) attend in May 2025?
What clinical data will OCUL present at ARVO 2025 about OTX-TKI?
How many scientific presentations will Ocular Therapeutix make at Retina World Congress 2025?
What is OCUL presenting at Eyecelerator 2025 about drug delivery?
What are the key OCUL research findings being presented about diabetic retinopathy in May 2025?
